Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

NCT00628251 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: AZD2281
DRUG: Liposomal Doxorubicin
DRUG: AZD2281

Sponsor

AstraZeneca